{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-066613","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.234493+00:00","generated_at":"2026-05-31T11:21:00.135384+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cadrenal Therapeutics Provides Q2 2024 Corporate Update and Financial Results","bullets":["Collaborated with Abbott to advance tecarfarin for LVAD patients using HeartMate 3 device.","Received FDA Orphan Drug Designation in April 2024 for preventing blood clots and strokes in LVAD patients.","Q2 2024 operating expenses (ex-non-cash) totaled $2.3 million; cash used in operations was $1.5 million.","Cash balance as of June 30, 2024 was $5.0 million.","CEO Quang Pham highlighted progress on pivotal trial and LVAD study protocol development."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-066613","json":"https://secwatch.observer/filing/0001213900-24-066613.json","markdown":"https://secwatch.observer/filing/0001213900-24-066613.md","text":"https://secwatch.observer/filing/0001213900-24-066613.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024066613/0001213900-24-066613-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024066613/ea021083501-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:21:00.135384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}